Olga I. Evsyukova

Olga I. Evsyukova

Auto-generated profile, based on publicly available information

Olga I. Evsyukova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2019 in Cancer Urology
Verified
Journal Article
Open access
PDF file
ОEО. I. Evsyukova
О. I. Evsyukova
VMV. В. Matveev
V. В. Matveev
This review of renal cell carcinoma describes new diagnostics and treatment standards, new guidelines from international professional organizations and key studies, published in 2019.

12 May 2023 in Cancer Urology
Verified
Journal Article
Open access
PDF file
MVM. I. Volkova
M. I. Volkova
AKA. S. Kalpinskiy
A. S. Kalpinskiy
KMK. V. Men'SHikov
K. V. Men'SHikov
LGL. V. Gorbuleva
L. V. Gorbuleva
OEO. I. Evsyukova
O. I. Evsyukova
BAB. Ya. Alekseev
B. Ya. Alekseev
Purpose: an assessment of efficacy and safety of cabozantinib in unselected patients with metastatic renal cell carcinoma in the first and subsequent lines of therapy.Materials and methods. Russian multicenter observational study included 92 consecutive patients with morphologically verified metastatic renal cell carcinoma treated with cabozantinib (60 mg/d) in 16 Russian centers. Median age of the patients was 56 (19-79) years, a male-to-female ratio - 3:1. At the start of cabozantinib therapy 27.2 % of patients had ECOG PS 2. Most common histological type of kidney cancer was clear-cell RCC (90.2 %). Most patients were diagnosed with synchronous (71.7 %) multiple metastases (60.9 %). Previous nephrectomy was performed in 87.0 % of cases. Prognosis according to International Metastatic Renal Cancer Database Consortium (IMDC) score was assessed as favorable in 5.4 %, intermediate - in 58.7 % and poor - in 35.9 % patients. Cabozantinib as the first-line therapy was administered in 9 (9.8 %), following 1-5 lines of systemic treatment - in 83 (90.2 %) cases. Median follow-up was 11 (2.3-44.5) months.Results. In patients, receiving cabozantinib as the first-line therapy, objective response rate was 66.7 %, tumor control was reached in 100 % of cases. Median time to the objective response was 2.6 (1.9-3.6) months, median objective response duration - 13.2 (6.2-21.5) months. Median progression-free survival (PFS) and overall survival (OS) were not reached, 6- and 12-months PFS was 77.8 % and 77.8 %, 6- and 12-months OS - 88.9 % and 88.9 % respectively. Cabozantinib as the second and subsequent lines of therapy provided objective response rate of 34.9 %, tumor control rate - 97.6 %. Median time to the objective response was 2.5 (1.8-4.1) months, median objective response duration - 12.6 (5.5-27.3) months. Median PFS was not reached (6- and 12-months PFS - 92.5 % and 73.1 % respectively), median OS was 32.6 months (6- and 12-months OS - 97.4 % and 80.8 % respectively). Any adverse events (AE) developed in 88.8 %, AE grade III-IV - in 32.6 % of cases. Most frequent AE grade III-IV included arterial hypertension (18.5 %), diarrhea (6.5 %) and palmar-plantar erythrodysesthesia (6.5 %). Unacceptable toxicity demanded treatment cancellation in 2.2 %, therapy interruption - in 16.3 % and dose reduction - in 30.4 % of patients.Conclusion. Cabozantinib as the first and subsequent lines of therapy for metastatic renal cell carcinoma patients in the real world practice demonstrated high efficacy and better tolerability comparing with population assigned for cabozantinib monotherapy in the randomized phase II-III trials.

30 December 2020 in Cancer Urology
Verified
Journal Article
Open access
PDF file
VMV. B. Matveev
V. B. Matveev
OKO. A. Khalmurzaev
O. A. Khalmurzaev
OEO. I. Evsyukova
O. I. Evsyukova
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.

30 September 2019 in Cancer Urology
Verified
Journal Article
Open access
PDF file
MVM. I. Volkova
M. I. Volkova
ААА. М. Абдельгафур
А. М. Абдельгафур
MAM. T. Aivazov
M. T. Aivazov
ZAZ. V. Amoev
Z. V. Amoev
KBK. G. Babina
K. G. Babina
ISI. E. Shumskaya
I. E. Shumskaya
Objective: an assessment of efficacy and safety of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line of antiangiogenic targeted therapy.Material. Russian multicenter observational study ROSLERCM included 73 consecutive patients with morphologically verified mRCC progressed during or following ≥1 line of antiangiogenic targeted therapy, treated with lenvatinib (18 mg/d) and everolimus (5 mg/d) in 20 Russian centers. Median age of the patients was 59 (23–73) years, a male-to-female ratio – 3:1. Most common histological type of kidney cancer was clear-cell RCC (71 (95.8 %)). More than 2 lines of previous therapy were administered in 45 (61.6 %) cases. Most patients were diagnosed with multiple metastases (71 (97.3 %)) in 1 site (61 (83.6 %)). Nephrectomy was performed in 87.7 % (64/73) of cases. At the combined therapy start ECOG PS 2–4 was registered in 16 (20.5 %), poor prognosis according to IMDC score – in 33 (45.2 %) patients. Median follow-up was 9.7 (1–26) months.Results. Median progression-free survival achieved 16.9 (95 % confidence intervals (CI) 12.1–20.6), overall survival – 20.8 (95 % CI 15.7–25.9) months. Objective response rate was 11 % (8/73); tumor control was reached in 93.2 % (68/73) of cases. Median objective response duration was 10.5 (4.3–16.8) months, tumor control duration – 10.0 (2.5–17.5) months. Any adverse events developed in 83.6 % (61/73), adverse events grade III–V – in 23.3 % (17/73) of cases. Most frequent AE grade III–IV were diarrhea (10 (13.6 %)) and arterial hypertension (6 (8.2 %)). Unacceptable toxicity demanded treatment cancellation in 4.2 % (3/73), therapy interruption – in 30.1 % (22/73) and dose reduction – in 32.9 % (24/73) of patients.Conclusion. Unselected mRCC patients administered with combined targeted therapy in the real world practice were registered with similar survival, lower objective response rate, and better tolerability comparing with population assigned for lenvatinib plus everolimus in the randomized phase II trial.

30 December 2017 in Cancer Urology
Verified
Journal Article
Open access
PDF file
OEO. I. Evsukova
O. I. Evsukova
VCV. A. Chernyaev
V. A. Chernyaev
OKO. A. Khalmurzaev
O. A. Khalmurzaev
KKK. A. Khafizov
K. A. Khafizov
AKA. V. Khachaturyan
A. V. Khachaturyan
VMV. B. Matveev
V. B. Matveev
Background. The rate of prostate cancer progression after radical treatment is about 40 %. Currently, some data suggest that patients with oligometastases have a more favorable prognosis than patients with extensive tumor lesions. In 78 % of cases, oligometastases are localized in the pelvic and retroperitoneal lymph nodes. Surgical removal of all detectable metastases can cure prostate cancer recurrence, however the possibility of using salvage lymph node dissection (sLND) in clinical practice remains limited due to the lack of data on surgical and oncological outcomes of this treatment method.The study objective is to evaluate surgical and early oncological outcomes of sLND in patients with progressive prostate cancer after radical treatment.Materials and methods. The study was conducted at the N.N. Blokhin National Medical Research Center of Oncology. The analysis included 17 patients with biochemical prostate cancer recurrence and symptoms of lymphogenic disease progression based on positron emission tomography/computed tomography with radiopharmaceuticals 18F-choline (n = 14; 82.35 %) and 68Ga-prostate-specific membrane antigen (n = 1; 5.88 %) and magnetic resonance lymphography with Combidex (ultra-small superparamagnetic iron oxides, USPIO) (n = 2; 12.0 %). All patients underwent sLND in the period from October of 2014 to December of 2016.Results. Postoperative complications were observed in 58.8 % (n = 10) of cases. No grade III and IV complications per the Clavien–Dindo classification were registered. For median follow up duration of 17.5 (5–31) months, full biochemical response in the form of decreased prostate-specific antigen 0.2 ng/ml was observed in 5 (29.4 %) patients. Mean time to prescription of hormone therapy was 6.6 (1–12) months. Considering this follow up duration, 53 % of patients hadn’t received hormone therapy.Conclusion. Therefore, sLND is a safe surgical intervention with low number of severe complications. sLND can be successfully used in wellselected patients as a diagnostic tool and provide accurate information on the state of lymph nodes. Removal of oligometastases allows to achieve long-term relapse-free period in individual patients and postpone prescription of hormone therapy.

30 March 2018 in Cancer Urology
Verified
Journal Article
Open access
PDF file
MVM. I. Volkova
M. I. Volkova
OEO. I. Evsyukova
O. I. Evsyukova
AOA. S. Olshanskaya
A. S. Olshanskaya
VMV. B. Matveev
V. B. Matveev
Objective: a preliminary assessment of safety, tolerability, and efficacy of lenvatinib in combination with everolimus in unselected patients with metastatic renal cell carcinoma (mRCC) resistant to antiangiogenic targeted therapy.Materials and methods. We analyzed medical data of 19 consecutive mRCC patients received lenvatinib in combination with everolimus following antiangiogenic targeted therapy failure. Median age was 55 (23–73) years. ECOG PS 0–1 was in 11 (57.9 %), ECOG 2–4 – in 8 (42.1 %) cases. Four (21.1 %) patients were distributed into the good, 10 (52.6 %) – into the intermediate, and 5 (26.3 %) – into the poor IMDC (International Metastatic Renal Cancer Database Consortium) prognostic group. Multiple metastases were diagnosed in 18 (94.7 %), multiple metastatic sites – in 17 (89.5 %), liver metastases – in 6 (37.6 %) cases. All the patients were previously treated with 1–4 lines of therapy (≥2 – 12 (63.1 %)). Median follow-up was 5 (2–10) months.Results. By the time of the analysis 12 (63.2 %) patients are being treated, 7 (36.8 %) – completed combined treatment (due to RCC progression – 4 (21.1 %), toxicity – 2 (10.5 %), death from unrelated reason – 1 (5.3 %)). Median time of completed therapy was not reached, mean treatment time was 5.1 (1.9–11.2) months. Adverse events were registered in 17 (89.5 %) patients (grade III – 3 (15.8 %), grade IV – 0, grade V – 1 (5.3 %)). The most common adverse events were diarrhea (68.4 %), stomatitis (57.9 %), hypertension (42.1 %), and weight loss (47.4 %). Lenvatinib or everolimus dose reduction was demanded in 5 (26.3 %) and 0, therapy interruption – in 5 (26.3 %) and 1 (5.3 %) patient respectively. Maximal response was assessed as partial in 1 (5.3 %) and stabilization – in 18 (94.7 %) cases. Decline of metastases size was registered in 12 (63.2 %) (median – 17 % (3–40 %)), stabilization – in 8 (42.1 %), enlargement – in 1 (5.3 %) patient. Median time to maximal response was 2 (2–4) months. Five-months overall and progression-free survival rates were 76.1 and 87.4 % respectively. Following 2 cycles of combined therapy ECOG PS improved in 11 (57.9 %), stabilized – in 6 (31.6 %), worsened – in 2 (10.5 %) patients.Conclusion. Our preliminary data have confirmed antitumor activity and showed acceptable tolerability of lenvatinib in combination with everolimus in unselected patients with mRCC resistant to antiangiogenic targeted therapy.